scholarly journals Exosomal circRNAs: Emerging Players in Tumor Metastasis

2021 ◽  
Vol 9 ◽  
Author(s):  
Hao Zhou ◽  
Xiaoyun He ◽  
Yuxiang He ◽  
Chunlin Ou ◽  
Pengfei Cao
Keyword(s):  
Cancer Patients ◽  
Poor Prognosis ◽  
Tumor Metastasis ◽  
Malignant Tumors ◽  
Tumor Therapy ◽  
Clinical Applications ◽  
Secretory Cells ◽  
Diagnostic Biomarkers ◽  
Cell Metastasis ◽  
Tumor Cell Metastasis

Metastasis is an important feature of malignant tumors, and is the primary cause of poor prognosis and treatment failure, in addition to representing a potentially fatal challenge for cancer patients. Exosomes are small extracellular vesicles 30–150 nm in diameter that transmit cargo, such as DNA, RNA, and proteins, as a means of intercellular communication. Exosomes play crucial roles in a range of human diseases, especially malignant tumors. A growing number of studies have verified that circRNAs can be enveloped in exosomes and transferred from secretory cells to recipient cells, thereby regulating tumor progression, especially tumor metastasis. Exosomal circRNAs regulate tumor cell metastasis not only by regulating the signaling pathways, but also by affecting the tumor microenvironment. Moreover, exosomal circRNAs have the potential to serve as valuable diagnostic biomarkers and novel therapeutic targets in cancer patients. In this review, we summarize the mechanism by which exosomal circRNAs modulate metastatic phenomena in various types of tumors, and put forward the prospects of clinical applications of exosomal circRNAs in tumor therapy.

scholarly journals FoxM1 Is Associated with Poor Prognosis of Non-Small Cell Lung Cancer Patients through Promoting Tumor Metastasis

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e59412 ◽  
Author(s):  
Nuo Xu ◽  
Deshui Jia ◽  
Wenfeng Chen ◽  
Hao Wang ◽  
Fanglei Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Tumor Metastasis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals MACC1 upregulation promotes gastric cancer tumor cell metastasis and predicts a poor prognosis

2016 ◽  
Vol 17 (5) ◽  
pp. 361-366 ◽  
Author(s):  
Qiu-ping Xie ◽  
Cheng Xiang ◽  
Gang Wang ◽  
Ke-feng Lei ◽  
Yong Wang
Keyword(s):  
Gastric Cancer ◽  
Tumor Cell ◽  
Poor Prognosis ◽  
Cell Metastasis ◽  
Tumor Cell Metastasis ◽  
Cancer Tumor

scholarly journals Discovery and Biological Evaluation of CD147 N-Glycan Inhibitors: A New Direction in the Treatment of Tumor Metastasis

Molecules ◽  
2020 ◽  
Vol 26 (1) ◽  
pp. 33
Author(s):  
Wenqian Li ◽  
Daojiong Wang ◽  
Yushu Ge ◽  
Lei Zhang ◽  
Jiang Wu ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Tumor Metastasis ◽  
Malignant Tumors ◽  
Biological Evaluation ◽  
The Other ◽  
Hela Cell Line ◽  
The Poor ◽  
Computer Aided ◽  
Cancer Types ◽  
Specific Inhibitors

N-glycosylation is instrumental to the regulation of CD147 functions, including the maturation of CD147, secretion of matrix metalloproteinases (MMPs), and promotion of tumor metastasis. Glycosylated CD147 is highly expressed in various cancer types, participates in metastasis, and is associated with the poor prognosis of malignant tumors. However, to date, there has been little development of target-specific inhibitors for CD147 glycosylation. In this work, we report a strategy for discovering CD147 glycosylation inhibitors through computer-aided screening and inhibition assays. Four compounds were screened as potential CD147 glycosylation inhibitors. Of these, compound 72 was finally identified as the best candidate. Further experiments confirmed that compound 72 inhibited the production of MMPs and the metastasis of cancer cells in the Hela cell line. Results further suggest that compound 72 could promote the expression of E-cadherin by targeting CD147, thereby inhibiting tumor migration. Finally, the structures of the other potential CD147 N-glycosylation inhibitors may eventually provide guidance for future optimization.

scholarly journals Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

2021 ◽  
Vol 12 ◽  
Author(s):  
Mancheng Gong ◽  
Erlin Song ◽  
Guiying Huang ◽  
Wenjun Ni ◽  
Wenjing Dong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Malignant Tumors ◽  
High Expression ◽  
Prognostic Indicators ◽  
Bladder Tissue ◽  
Normal Bladder ◽  
Tcga Dataset

Bladder cancer is one of the most common urogenital malignancies in the world, and there are no adequate prognostic indicators. CNTD2 is one of the atypical cyclins, which may be related to the cell cycle and even the development of cancers. Early studies have shown that CNTD2 is closely related to the occurrence and development of many malignant tumors. However, the mechanism of CNTD2 in bladder cancer has not been reported. In our research, we explored the different expressions of CNTD2 between 411 bladder cancers and 19 normal bladder tissues based on the TCGA dataset. CNTD2-related signaling pathways were identified through the GSEA. We analyzed the associations of CNTD2 expression and bladder cancer progression and survival using GSE13507. Compared with 19 cases of normal bladder tissue, CNTD2 gene expression was increased in 411 cases of bladder cancer. The high expression of CNTD2 strongly correlated with grade (P < 0.0001), T classification (P = 0.0001), N classification (P = 0.00011), M classification (P = 0.044), age (P = 0.027), and gender (P = 0.0012). Bladder cancer patients with high CNTD2 expression had shorter overall survival (P < 0.001). In the meantime, univariate and multivariate analyses showed that the increased expression of CNTD2 was an independent factor for poor prognosis in bladder cancer patients (P < 0.001 and P < 0.001, respectively). CNTD2 expression is closely related to bladder cancer progression, and the high expression of CNTD2 may be an adverse biomarker in bladder cancer patients.

scholarly journals Identification of KIF23 as a prognostic signature for ovarian cancer based on large scale samples and clinical validation

2020 ◽  
Author(s):  
Yuexin Hu ◽  
Mingjun Zheng ◽  
Caixia Wang ◽  
Shuang Wang ◽  
Rui Gou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Large Scale ◽  
Cox Regression ◽  
Malignant Tumors ◽  
Chemotherapy Resistance ◽  
Survival Prognosis ◽  
Molecular Targeted Drug

Abstract Background: Ovarian cancer is one of the common malignant tumors in gynecology. Although the treatment strategy for ovarian cancer has been greatly improved in recent years, due to the metastasis, recurrence and drug resistance, the 5-year overall survival rate of patients is still less than 47%. However, at present, there is no specific markers for clinical application. The purpose of this study is to verify the expression and clinical significance of KIF23 in ovarian cancer and identify potential targets for the clinical treatment of ovarian cancer. Methods: The expression of KIF23 in ovarian cancer tissues and its relationship between survival prognosis and clinical pathological parameters were analyzed in Oncomine, GEO, and TCGA databases. KIF23 expression was analyzed by Kaplan-Meier plotter database and its relationship with chemo-resistance was studied. The molecular mechanism involved in KIF23 was analyzed from the perspective of gene mutation, copy number variation and other genomics. Finally, immunohistochemistry experiment was used to verify the expression of KIF2, and its relationship between the clinical pathological parameters and prognosis of ovarian cancer patients was analyzed by single factor and multivariate Cox regression models. Results: Bioinformatic and experimental results have demonstrated that KIF23 is highly expressed in ovarian cancer, and its high expression is positively correlated with poor prognosis. Overexpression of KIF23 can cause chemotherapy resistance in ovarian cancer and affect the overall survival of patients. Genomics analysis showed that KIF23 expression was associated with mutations such as FLG2 and TTN, and it was significantly enriched in tumor signaling pathways such as DNA replication and cell cycle. Conclusions: KIF23 can not only be used as a biomarker of poor prognosis in patients with various stages of ovarian cancer, but also be used as a molecular targeted drug and an independent prognostic biomarker for the treatment of ovarian cancer patients.

scholarly journals Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Lidong Cao ◽  
Jiacheng Wu ◽  
Xianzhi Qu ◽  
Jiyao Sheng ◽  
Mengying Cui ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Cancer Cells ◽  
Biochemical Parameters ◽  
Malignant Tumors ◽  
Aerobic Glycolysis ◽  
Clinical Applications ◽  
Common Type ◽  
Ductal Adenocarcinoma ◽  
Diagnostic Biomarkers

AbstractPancreatic cancer is one of the most malignant tumors worldwide, and pancreatic ductal adenocarcinoma is the most common type. In pancreatic cancer, glycolysis is the primary way energy is produced to maintain the proliferation, invasion, migration, and metastasis of cancer cells, even under normoxia. However, the potential molecular mechanism is still unknown. From this perspective, this review mainly aimed to summarize the current reasonable interpretation of aerobic glycolysis in pancreatic cancer and some of the newest methods for the detection and treatment of pancreatic cancer. More specifically, we reported some biochemical parameters, such as newly developed enzymes and transporters, and further explored their potential as diagnostic biomarkers and therapeutic targets.

scholarly journals Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis

2019 ◽  
Vol 99 (6) ◽  
pp. 736-748 ◽  
Author(s):  
Longfei Dai ◽  
Wendi Hu ◽  
Zhenjie Yang ◽  
Diyu Chen ◽  
Bin He ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Intrahepatic Cholangiocarcinoma ◽  
Poor Prognosis ◽  
Cell Metastasis ◽  
Tumor Cell Metastasis

scholarly journals Role of Metastasis Suppressor KAI1/CD82 in Different Cancers

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Wei Yan ◽  
Jinny Huang ◽  
Qian Zhang ◽  
Jian Zhang
Keyword(s):  
Poor Prognosis ◽  
Tumor Metastasis ◽  
Malignant Tumors ◽  
Suppressor Gene ◽  
Tumor Formation ◽  
Metastasis Suppressor ◽  
Metastasis Suppressor Gene ◽  
Metastasis Suppressor Genes ◽  
Potential Strategy

Metastasis is one of the characteristics of malignant tumors and the main cause of death worldwide. The process of metastasis is mainly affected by tumor metastasis genes, tumor metastasis suppressor genes, tumor microenvironment, extracellular matrix degradation, and other factors. Thus, it is essential to elucidate the mechanism of metastasis and find the therapeutic targets in order to prevent the development of malignant tumors. KAI1/CD82, a member of tetraspanin superfamily of glycoproteins, has been reported as a tumor metastasis suppressor gene in various types of cancers without affecting the tumor formation. Many studies have demonstrated that low expression of KAI1/CD82 might lead to poor prognosis due to its interactions with other tetraspanins and integrins, resulting in the regulation of cell motility and invasion, cell-cell adhesion, and apoptosis. Considering its pathological and physiological significance, KAI1/CD82 could be a potential strategy for clinical predicting and preventing tumor progression and metastasis. The present review aims to discuss the role of KAI1/CD82 in metastasis for different cancers and examine its prospects as a metastasis biomarker and a therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document